ME Therapeutics Holdings IncCanadian Securities Exchange:METXView on OTC Pink - Current Information
- LAST PRICE3.8500
- TODAY'S CHANGE (%)-0.0500 (-1.2821%)
- Bid / Lots3.2500/ 1
- Ask / Lots3.9000/ 5
- Open / Previous Close3.5000 / 3.9000
- Day Range
- 52 Week Range
- Volume1,100
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | METX |
|---|---|---|
| 12:28 ET | 300 | 3 |
| 12:35 ET | 300 | 3 |
| 12:50 ET | 100 | 3.9 |
| 01:47 ET | 200 | 3.85 |
| 03:39 ET | 200 | 3.85 |
Oct 25, 2024
ME Therapeutics Holdings Inc. Appoints Chief Business Officer, from 9:02AM ET on Friday Oct 25, 2024 by Dow Jones
9:02AM ET on Friday Oct 25, 2024 by Dow Jones
Oct 22, 2024
ME Therapeutics Holdings Inc. Provides Research and Development Update and Corporate Update, from 6:03AM ET on Tuesday Oct 22, 2024 by Dow Jones
6:03AM ET on Tuesday Oct 22, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
ME Therapeutics Holdings Inc | 98.2M | -23.3x | --- |
Satellos Bioscience Inc | 96.4M | -4.0x | --- |
Oncolytics Biotech Inc | 106.3M | -3.8x | --- |
Medicenna Therapeutics Corp | 110.8M | -4.3x | --- |
MustGrow Biologics Corp | 98.8M | -238.2x | --- |
Alpha Cognition Inc | 48.6M | -1.7x | --- |
Company Information
ME Therapeutics Holdings Inc. is a Canada-based biotechnology company. The Company is involved in the discovery and development of novel immuno oncology therapeutics targeting immune suppression in cancer. The Company’s lead candidate is a novel high affinity antibody drug that targets a key protein involved in the generation of suppressive myeloid cells. This antibody drug candidate is being developed to treat colorectal cancer. In addition, to its antibody drug candidate program, the Company is also developing a novel small molecule prodrug candidate designed to specifically target suppressive myeloid cells in the tumor environment. Its two development programs include its anti-G-CSF antibody and its myeloid target prodrug and are engaged in a discovery program to discover novel lipid nanoparticle formulations. Its anti-G-CSF antibody candidate (h1B11-12) is its advanced preclinical asset.
Contact Information
- Headquarters
- 177 Robson StreetVANCOUVER, BC, Canada V6B 0N3
- Phone
- ---
- Fax
- ---
Executives
- Chief Executive Officer, Director
- Salim Dhanji
- Chief Financial Officer
- Quinn Martin
- Corporate Secretary
- Jamil Kassam
- Independent Director
- Kenneth Harder
- Independent Director
- Karim Nanji
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $98.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 25.2M |
ME Therapeutics Holdings Inc does not pay a dividend. | |
Beta | --- |
EPS | $-0.17 |
Book Value | $0.02 |
P/E Ratio | -23.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
